Tokushima University / Educator and Researcher Directory --- Nakayama, Tomohiko

Search:

Tokushima University ⟩ University Hospital ⟩ 先端医科医療開発研究プロジェクト ⟩
Tokushima University ⟩ University Hospital ⟩ Clinical Division ⟩ Department of Neurosurgery, Psychiatry and Anesthesiology ⟩ Psychiatry ⟩
Tokushima University ⟩ University Hospital ⟩ Clinical Division ⟩ Department of Neurosurgery, Psychiatry and Anesthesiology ⟩ Psychosomatic Medicine ⟩

(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Toshiyuki Shirai, Satoshi Okazaki, Takaki Tanifuji, Shusuke Numata, Tomohiko Nakayama, Tomohiro Yoshida, Kentaro Mouri, Ikuo Otsuka, Noboru Hiroi and Akitoyo Hishimoto : Meta-analyses of epigenetic age acceleration and GrimAge components of schizophrenia or first-episode psychosis., Schizophrenia, Vol.10, No.1, 108, 2024. (Summary) Schizophrenia is a common chronic psychiatric disorder that causes age-related dysfunction. The life expectancy in patients with schizophrenia is 10 years shorter than that in the general population because of the higher risk of other diseases, such as cardiovascular diseases. Aging studies based on DNA methylation status have received considerable attention. Several epigenetic age accelerations and predicted values of aging-related proteins (GrimAge and GrimAge2 components) have been analyzed in multiple diseases. However, no studies have investigated up to GrimAge and GrimAge2 components between patients with schizophrenia and controls. Therefore, we aimed to conduct multiple regression analyses to investigate the association between schizophrenia and epigenetic age accelerations and GrimAge and GrimAge2 components in seven cohorts. Furthermore, we included patients with first-episode psychosis whose illness duration was often shorter than schizophrenia in our analysis. We integrated these results with meta-analyses, noting the acceleration of GrimAge, GrimAge2, and DunedinPACE, and increase in adrenomedullin, beta-2 microglobulin, cystatin C, and plasminogen activation inhibitor-1 levels, in patients with schizophrenia or first-episode psychosis. These results corroborated the finding that patients with schizophrenia had an increased risk of diabetes, cardiovascular disease, and cognitive dysfunction from a biological perspective. Patients with schizophrenia and first-episode psychosis showed differences in the results when compared with controls. Such analyses may lead to the development of novel therapeutic targets to patients with schizophrenia or relevant diseases from the perspective of aging in the future. (Link to Publication Site) ● Publication site (DOI): 10.1038/s41537-024-00531-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39548083 ● Search Scopus @ Elsevier (PMID): 39548083 ● Search Scopus @ Elsevier (DOI): 10.1038/s41537-024-00531-8 (DOI: 10.1038/s41537-024-00531-8, PubMed: 39548083)
2.	Tomoki Ozaki, Yuta Yoshino, Ayumi Tachibana, Hideaki Shimizu, Takaaki Mori, Tomohiko Nakayama, Kazuaki Mawatari, Shusuke Numata, Junichi Iga, Akira Takahashi, Tetsuro Ohmori and Shu-ichi Ueno : Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer's disease (from the Nakayama Study)., Scientific Reports, Vol.12, No.1, 15205, 2022. (Summary) Alzheimer's disease (AD) is a progressive disease, and the number of AD patients is increasing every year as the population ages. One of the pathophysiological mechanisms of AD is thought to be the effect of metabolomic abnormalities. There have been several studies of metabolomic abnormalities of AD, and new biomarkers are being investigated. Metabolomic studies have been attracting attention, and the aim of this study was to identify metabolomic biomarkers associated with AD and mild cognitive impairment (MCI). Of the 927 participants in the Nakayama Study conducted in Iyo City, Ehime Prefecture, 106 were selected for this study as Control (n = 40), MCI (n = 26), and AD (n = 40) groups, matched by age and sex. Metabolomic comparisons were made across the three groups. Then, correlations between metabolites and clinical symptoms were examined. The blood mRNA levels of the ornithine metabolic enzymes were also measured. Of the plasma metabolites, significant differences were found in ornithine, uracil, and lysine. Ornithine was significantly decreased in the AD group compared to the Control and MCI groups (Control vs. AD: 97.2 vs. 77.4; P = 0.01, MCI vs. AD: 92.5 vs. 77.4; P = 0.02). Uracil and lysine were also significantly decreased in the AD group compared to the Control group (uracil, Control vs. AD: 272 vs. 235; P = 0.04, lysine, Control vs. AD: 208 vs. 176; P = 0.03). In the total sample, the MMSE score was significantly correlated with lysine, ornithine, thymine, and uracil. The Barthel index score was significantly correlated with lysine. The instrumental activities of daily living (IADL) score were significantly correlated with lysine, betaine, creatine, and thymine. In the ornithine metabolism pathway, the spermine synthase mRNA level was significantly decreased in AD. Ornithine was decreased, and mRNA expressions related to its metabolism were changed in the AD group compared to the Control and MCI groups, suggesting an association between abnormal ornithine metabolism and AD. Increased betaine and decreased methionine may also have the potential to serve as markers of higher IADL in elderly persons. Plasma metabolites may be useful for predicting the progression of AD. (Keyword) Activities of Daily Living / Aged / Alzheimer Disease / Betaine / Biomarkers / Cognitive Dysfunction / Humans / Lysine / Ornithine / plasma / RNA, Messenger / Thymine (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-022-19670-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36075959 ● Search Scopus @ Elsevier (PMID): 36075959 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-19670-y (DOI: 10.1038/s41598-022-19670-y, PubMed: 36075959)
3.	Yukiko Tomioka, Makoto Kinoshita, Hidehiro Umehara, Tomohiko Nakayama, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : Association between serum folate levels and schizophrenia based on sex., Psychiatry and Clinical Neurosciences, Vol.74, No.9, 466-471, 2020. (Summary) Our findings suggest that: (i) a low serum folate level may be associated with schizophrenia regardless of sex; and (ii) folate administration may be beneficial for the treatment of schizophrenia. In schizophrenic patients with low serum folate levels, folate administration might result in improvements in high tHcy and an increase in low vitamin B6 levels. (Tokushima University Institutional Repository) ● Metadata: 2008327 (Link to Publication Site) ● Publication site (DOI): 10.1111/pcn.13074 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32445495 ● Search Scopus @ Elsevier (PMID): 32445495 ● Search Scopus @ Elsevier (DOI): 10.1111/pcn.13074 (Tokushima University Institutional Repository: 2008327, DOI: 10.1111/pcn.13074, PubMed: 32445495)

Review, Commentary:

1.	Tomohiko Nakayama, Yukiko Tomioka, Naoki Yamada, Hidehiro Umehara, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : 臨床現場におけるたとえ話, Japanese Journal of Psychiatric Treatment, Vol.37, No.7, 745-749, Jul. 2022. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520856045142110592 (CiNii: 1520856045142110592)
2.	Tomohiko Nakayama, Shusuke Numata and Tetsuro Ohmori : 精神病性うつ病, Psychiatry, Vol.37, No.3, 268-272, Sep. 2020. (Keyword) psychotic depression / catatonic depression / involutional melancholia / DSM-5 / ICD-11 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520010381187289088 (CiNii: 1520010381187289088)

Proceeding of International Conference:

1.	Tomohiko Nakayama, Hiroaki Edo, Yoshida Tomohiro, Matsumoto Yui, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : Nortriptyline Therapy of Treatment-Resistant Depression: two case reports, The CINP 2021 Virtual World Congress, Online, Feb. 2021.

Proceeding of Domestic Conference:

1.	Tomohiko Nakayama, Yui Matsumoto, Yukiko Tomioka, Naoki Yamada, Masahito Nakataki and Shusuke Numata : 長期間維持電気けいれん療法を施行している遅発緊張病の一例, 第36回日本総合病院精神医学会総会, Nov. 2023.
2.	塩田恭史, Tomohiko Nakayama, Naoki Yamada, Masahito Nakataki and Shusuke Numata : 脳梗塞と転換症状の鑑別を要したうつ病の一例, 第63回中国・四国精神神経学会, Nov. 2023.
3.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, Yui Matsumoto, Tomohiro Yoshida, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 大うつ病性障害患者における治療前後の血中代謝物濃度の変化, 第45回日本生物学的精神医学会年会, Nov. 2023.
4.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, Yui Matsumoto, Tomohiro Yoshida, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 双極性障害における血中代謝物の変化, 第33回日本臨床精神神経薬理学会学術集会, Sep. 2023.
5.	Tomohiko Nakayama, Ryutaro Muguruma, Saaya Tada, Mika Takahara, Ryosuke Miyamoto, Masahito Nakataki, Yuishin Izumi and Shusuke Numata : 難治性うつ病として治療中にレビー小体病が明らかとなった1症例, 第22回日本早期認知症学会学術大会, Sep. 2022.
6.	Yukiko Tomioka, Makoto Kinoshita, Tomohiko Nakayama, Hidehiro Umehara, Masahito Nakataki and Shusuke Numata : 統合失調症患者におけるDNMT1と3aの遺伝子発現量の検討, 第16回日本統合失調症学会, Mar. 2022.
7.	六車隆太郎, 多田紗彩, Tomohiko Nakayama, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : うつ病の治療経過中にパーキンソン病の併存が明らかになった1症例, 【第61回中国・四国精神神経学会, Nov. 2021.
8.	青木真理子, Tomohiko Nakayama, Yukiko Tomioka, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : 診断に苦慮した遅発緊張病の一例, 第61回中国・四国精神神経学会, Nov. 2021.

Et cetera, Workshop:

1.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 双極性障害における血中メタボローム解析, 第42回躁うつ病の薬理・生化学的研究懇話会, Oct. 2023.
2.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 双極性障害における血中代謝物の変化, 第13回脳科学クラスターミニリトリート, Feb. 2022.
3.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Shusuke Numata, Akira Takahashi, 岡本泰昌 and Tetsuro Ohmori : うつ病におけるキヌレニン経路の変化, 第40回躁うつ病の薬理・生化学的研究懇話会, Oct. 2021.
4.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Shusuke Numata, Akira Takahashi, 岡本泰昌 and Tetsuro Ohmori : うつ病におけるキヌレニン経路の変化, 第12回脳科学クラスターミニリトリート, Feb. 2021.
5.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Shusuke Numata, Akira Takahashi, 岡本泰昌 and Tetsuro Ohmori : うつ病におけるキヌレニン経路の変化, 第5回メタボロームシンポジウム, Dec. 2020.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Search by Researcher Number (30872147)